By EP News Bureau - Jun 18,2020
Roche Products stated that it is expanding its presence in different states in India by increasing its field force in a phased manner and investing in new talent in India over the next few months
Roche Pharma and Entero Healthcare Solutions announced that the two companies have entered into an agreement under which, Entero will be responsible for promotion, marketing and distribution of Roche Pharma’s key nephrology drugs viz., Mycophenolate Mofetil (Cellcept), Valganciclovir (Valcyte), Epoetin Beta (NeoRecormon), and Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in India.
Roche Products stated that it is expanding its presence in different states in India by increasing its field force in a phased manner and investing in new talent in India over the next few months. The partnership deal, the discussions for which has been going on for the last few months, will help the company focus on these states and capabilities. Currently, the company has more than 2000 people working across states and through various partners in India.
“While we keep working towards creating and enhancing the healthcare ecosystem in India, we need to differentiate between our existing products that can reach the patients at a faster pace through a valued partnership like this, and the newer innovative drugs that we can focus on bringing into India in next few years,” said V. Simpson Emmanuel, General Manager, Roche Products – India.
He added, ”At Roche Pharma India, we are focusing on strategic approaches to ensure robust access, better healthcare financing and overall enhanced healthcare ecosystem. A partnership in India for our Nephrology portfolio is one such important step in ensuring that we bring world-class medicines and healthcare solutions to our country through an esteemed partner like Entero Healthcare Solutions.We remain committed to transforming healthcare in India to become a benchmark for other emerging markets around the globe.”
Prabhat Agrawal, Co-founder and CEO, Entero Healthcare Solutions said, “We are delighted to enter this unique collaboration with Roche to be able to serve patient needs in the area of organ transplant and chronic kidney disease. There has been a significant rise in the number of patients with kidney related ailments and with Entero’s presence across major cities in India, we aspire to make these innovative set of medicines accessible to every patient.”
Entero, backed by OrbiMed (a leading global healthcare investment firm), is conceptualized to become the most preferred supply chain partner driven by integrated technology led solutions and scale advantages for all the stakeholders in the healthcare ecosystem.
Pfizer Products India Limited has signed a distribution agreement with Entero Healthcare Solutions Private Limited to market and sell the product in India region. Under this agreement, Entero will be responsible for promotion, marketing and distribution of Pfizer’s key critical care drug- Methyl Prednisolone Sodium Succinate (Solu Medrol) by meeting key accounts and healthcare professionals.
Doctors believe the unique Act-O-Vial advantage of Solu Medrol makes it easier to handle, provides effective and safe delivery of the drug and reduces the chances of cross-contamination.
This partnership aims to provide better access of Solu Medrol for patients across India.